TMCI · Treace Medical Concepts, Inc.
Market Cap
$289.73M
Shares
65.03M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.51
Open$4.56
Day$4.37–4.56
52W close$1.20–7.44
Avg vol 30d355K
Short int1.6M · 2.4% float · 5.4d
Short vol39%
Last earningsAug 7, 2026
DataApr 2021–Sep 2026
Filing10-Q · Aug 7
Up next
Next earnings call
Nov 6, 2026
Est · unconfirmed
· in 8 wks
filed Aug 7, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$205.31M
Trailing 12 months
Net income (TTM)
−$59.52M
Trailing 12 months
Revenue growth YoY
-4.2%
Year over year
Operating margin
-26.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-8.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$13.59M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.2%
Year over year · more shares
Price change (1Y)
-37.9%
Trailing year
Short interest
2.4%
Latest settlement · 5.4 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+53%
above
Price vs 50-day avg
+1%
above
RSI (14)
49
neutral
MACD trend
Negative
52-week position
53%
mid-range
Momentum
relative strength
1-month return
0%
trailing
6-month return
+264%
trailing
YTD return
+84%
this year
Relative strength
+246%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Distributing
-2% holders QoQ · +30 funds added
Insider flow
Accumulating
Net +$246.7K over 90 days · 0% sells
Short interest
Falling
2.40% of float · ▼ -2.2% MoM · 5.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
116 holders — near 3-yr low, contrarian setup
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
+2%
Y/Y
Gross margin
80%
contracting
EPS growth
−3%
Y/Y
Free cash flow
$-29.5M
Balance sheet
$46.6M
net debt
Quant / Vol
risk profile
Volatility
87%
annualized · 1-yr
Max drawdown
−84%
past year
ATR
6.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 7, 2026
Full-year 2026 revenue
· full year 2026
Initiated
$204M – $212M
prior FY $212.69M
midpoint −2.2% Y/Y
Prior guidance
period ended
· from the 8-K filed Aug 6, 2024
Revenue
· full-year 2024
$201M – $211M
Adjusted EBITDA
· full-year 2024
50%
Guided vs delivered
· last 3 settled
Revenue
full-year 2024
guided $201M – $211M
$209.36M
In line
Full year 2022 revenue
full year 2022
guided $125M – $130M
$141.84M
Beat +11.2%
Full year 2021 revenue
full year 2021
guided $90M – $95M
$94.42M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+53%
Bullish
Price vs 50-day avg
+1%
Bullish
RSI (14)
49
Neutral
MACD trend
Negative
Bearish
52-week position
53%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Distributing
-2% holders QoQ · +30 funds added
Insider flow
Accumulating
Net +$246.7K over 90 days · 0% sells
Short interest
Falling
2.40% of float · ▼ -2.2% MoM · 5.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
116 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $5 · 53%
Range high $7
vs 200-day avg +53%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TMCI
this stock
Treace Medical Concepts, Inc.
|
$289.73M | +84.1% | +1.6% | — | 2.4% |
|
ABT
Abbott Laboratories
|
$178.08B | -18.6% | +5.7% | 28.6 | 1.3% |
|
MDT
Medtronic plc
|
$117.19B | -5.3% | +8.4% | 22.6 | 0.9% |
|
SYK
Stryker Corp
|
$103.43B | -21.6% | +11.2% | 27.9 | 2.0% |
|
BSX
Boston Scientific Corp
|
$62.29B | -54.9% | +12.5% | 17.4 | 3.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TMCI | -7.6% | +0.0% | +263.7% | -4.0% | +84.1% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -6.4% | +1.8% | +245.9% | -3.7% | +72.0% |